Table A2.
Covariate | HR | 95% CI | P |
---|---|---|---|
At diagnosis | |||
Age | 1.0304 | 0.9723 to 1.0920 | .3123 |
Stage | 0.8785 | 0.4257 to 1.8131 | .7261 |
Grade | 1.2524 | 0.7551 to 2.0772 | .3832 |
Log PSA | 0.6617 | 0.3697 to 1.1841 | .1643 |
After diagnosis | |||
RT v RP | 1.2043 | 0.5097 to 2.8454 | .6718 |
Time to BR | 1.0002 | 0.9998 to 1.0006 | .2423 |
On study | |||
Log PSA before initiation of ADT | 1.7595 | 1.1462 to 2.7012 | .0098 |
PSA nadir > 0.1 ng/mL | 3.7148 | 1.4718 to 9.3762 | .0055 |
First off-treatment interval ≤ 40 weeks | 3.6754 | 1.3650 to 9.8959 | .0100 |
Abbreviations: CRPC, castration-resistant prostate cancer; HR, hazard ratio; PSA, prostate-specific antigen; RT, radiation therapy; RP, radical prostatectomy; BR, biochemical relapse; ADT, androgen deprivation therapy.